Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16718949 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL10049180 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL35889 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL27483811 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| Iodide SCHEMBL10383845 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL18434254 | 0.94 | SMN1; SMN2 (0.53) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL14712106 | 0.88 | TP53 (0.52) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL7853872 | 0.88 | TP53 (0.52) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| SCHEMBL14711275 | 0.88 | TP53 (0.52) | SMN1; SMN2BRD4TP53ALDH1A1POLB | |
| Tert-Butyl Formate SCHEMBL27675054 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20120029018-A1 | 9-SUBSTITUTED PHENANTHRENE BASED TYLOPHORINE DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | SMN1; SMN2 2209/4885BRD4 145/4885TP53 9/4885 |
| US-20120029018-A1 | 9-SUBSTITUTED PHENANTHRENE BASED TYLOPHORINE DERIVATIVES | ABCB1, TYMP, PAH | SMN1; SMN2 3046/4885BRD4 1876/4885TP53 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.